Rankings
▼
Calendar
URGN FY 2022 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$927M
FY 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$64M
+34.0% YoY
Gross Profit
$57M
88.1% margin
Operating Income
-$79M
-122.8% margin
Net Income
-$110M
-170.6% margin
EPS (Diluted)
$-4.79
Cash Flow
Operating Cash Flow
-$88M
Free Cash Flow
-$88M
Stock-Based Comp.
$11M
Balance Sheet
Total Assets
$136M
Total Liabilities
$225M
Stockholders' Equity
-$89M
Cash & Equivalents
$55M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$64M
$48M
+34.0%
Gross Profit
$57M
$43M
+32.2%
Operating Income
-$79M
-$92M
+14.4%
Net Income
-$110M
-$111M
+0.9%
← Q4 2021
All Quarters
Q1 2022 →